Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, Olema reports key information about its operations, financing activities, and clinical programs through forms such as 8-K, as well as registration statements and prospectus supplements.
Recent Olema 8-K filings include disclosures about an underwritten public offering of common stock conducted under an effective shelf registration statement on Form S-3, the termination of an at-the-market (ATM) prospectus under a sales agreement with TD Securities (USA) LLC, and clinical collaboration agreements with Pfizer to evaluate palazestrant plus atirmociclib in ER+/HER2- metastatic breast cancer. Other 8-Ks furnish press releases reporting quarterly financial results and updated data from Phase 1b/2 studies of palazestrant in combination with ribociclib in advanced or metastatic ER+/HER2- breast cancer.
Through Olema’s SEC filings, investors can review details of its capital-raising transactions, such as the size and terms of public offerings, the use of shelf registration statements on Form S-3, and the structure of underwriting agreements. Filings also identify the company’s registered securities, including its common stock listed under the symbol OLMA on The Nasdaq Global Select Market.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand material events, financial updates, and clinical or collaboration disclosures. Users can monitor new 8-Ks and other SEC reports in real time, track changes related to Olema’s clinical-stage oncology programs, and reference historical filings to follow the evolution of its palazestrant and OP-3136 pipelines and financing history.
Shane W. Kovacs reported proposed sales of Common Stock on Form 144 handled through Fidelity Brokerage Services LLC. The filing lists recent dispositions in the past three months:
Olami Medical submitted a Form 144 notice reporting a proposed resale of 20,000 common shares on
OLMA Form 144 filing reports proposed and recent sales of common stock by an insider. The excerpt shows Shane W. Kovacs sold 3,822 shares on
OLMA filer submitted a Form 144 reporting a proposed sale of 20,000 common shares by Fidelity Brokerage Services LLC. The filing also discloses recent reported sales by Shane W. Kovacs, including a sale of 100,000 shares for
Olema Pharmaceuticals reported that its VP of Finance and Controller, Sasha Lu Austin, acquired equity awards on February 2, 2026. The awards include a stock option for 29,250 shares at an exercise price of $0.00 and a grant of 11,700 shares of common stock, both recorded as awards rather than open-market purchases.
According to the vesting terms, 25% of the option shares vest on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. All holdings are reported as direct ownership.
Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company. As of January 30, 2026, Lu directly holds 4,488 shares of common stock and multiple stock option awards. These stock options are structured to vest monthly over multi‑year periods, with several grants featuring 25% vesting on specified initial dates and the remaining 75% vesting in equal monthly installments, all contingent on continued service with Olema.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 6,710,194 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.4% of the class as of 12/31/2025.
The stake is held through various Janus Henderson asset management subsidiaries in discretionary managed portfolios. These asset managers share voting and dispositive power over the shares, while the underlying managed portfolios receive all dividends and sale proceeds. No individual managed portfolio owns more than five percent of Olema’s common stock. Janus Henderson certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema.
Bain Capital Life Sciences Opportunities IV, L.P. has reported a passive ownership stake in Olema Pharmaceuticals, Inc. common stock on a Schedule 13G/A. As of December 31, 2025, it is deemed to beneficially own 8,508,641 shares, representing 9.99% of the outstanding common stock.
The position consists of 1,989,775 common shares and pre-funded warrants initially exercisable for up to 8,013,216 additional shares, but a 9.99% “Beneficial Ownership Blocker” caps how many warrant shares are counted for regulatory purposes. The filing states the securities were not acquired to change or influence control of Olema.
Olema Pharmaceuticals, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report that they now beneficially own 0 shares of Olema common stock, representing 0.00% of the class.
The filing confirms they have no sole or shared voting or dispositive power over Olema shares and that they own 5% or less of the outstanding common stock. Ownership percentages are calculated using 78,652,730 Olema common shares outstanding as of November 19, 2025, as disclosed in the company’s prospectus.
Olema Oncology insider plans additional stock sale under Rule 144. A holder has filed to sell 10,000 shares of Olema common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $238,498.19, targeting an approximate sale date of 02/12/2026.
The 10,000 shares were acquired on 06/15/2020 via restricted stock vesting from the issuer as compensation. In the past three months, the same seller disposed of 3,822 common shares for gross proceeds of $107,069.20 and 100,000 common shares for gross proceeds of $2,873,214.99.